HC Wainwright Reaffirms “Neutral” Rating for Sarepta Therapeutics (NASDAQ:SRPT)

HC Wainwright reaffirmed their neutral rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a report released on Thursday morning,Benzinga reports. The brokerage currently has a $40.00 price target on the biotechnology company’s stock.

Several other analysts also recently issued reports on SRPT. Piper Sandler reduced their price target on shares of Sarepta Therapeutics from $110.00 to $70.00 and set an “overweight” rating for the company in a research report on Wednesday, May 7th. Royal Bank of Canada dropped their price objective on shares of Sarepta Therapeutics from $87.00 to $58.00 and set a “sector perform” rating on the stock in a research note on Wednesday, May 7th. Scotiabank reduced their price objective on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating for the company in a report on Thursday, March 20th. Oppenheimer lowered their target price on shares of Sarepta Therapeutics from $184.00 to $123.00 and set an “outperform” rating on the stock in a report on Wednesday, May 7th. Finally, Deutsche Bank Aktiengesellschaft dropped their price target on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating on the stock in a research report on Wednesday, March 19th. Six research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $122.61.

Sarepta Therapeutics Stock Performance

Shares of Sarepta Therapeutics stock opened at $37.90 on Thursday. The business has a 50-day simple moving average of $54.60 and a 200 day simple moving average of $94.39. Sarepta Therapeutics has a one year low of $34.10 and a one year high of $173.25. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The firm has a market capitalization of $3.72 billion, a price-to-earnings ratio of 30.32 and a beta of 0.85.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing analysts’ consensus estimates of $2.20 by ($5.62). The firm had revenue of $744.86 million during the quarter, compared to analyst estimates of $685.75 million. Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. The company’s revenue was up 80.2% on a year-over-year basis. During the same period last year, the business posted $0.73 EPS. On average, research analysts anticipate that Sarepta Therapeutics will post 2.67 earnings per share for the current fiscal year.

Insider Activity at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the sale, the director now directly owns 27,812 shares in the company, valued at $2,771,187.68. The trade was a 8.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 7.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Sarepta Therapeutics

Several institutional investors have recently added to or reduced their stakes in SRPT. Park Avenue Securities LLC purchased a new position in Sarepta Therapeutics in the fourth quarter valued at about $205,000. UMB Bank n.a. raised its holdings in shares of Sarepta Therapeutics by 36.0% in the 4th quarter. UMB Bank n.a. now owns 521 shares of the biotechnology company’s stock worth $63,000 after purchasing an additional 138 shares during the period. MassMutual Private Wealth & Trust FSB lifted its stake in Sarepta Therapeutics by 169.6% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 156 shares during the last quarter. Nisa Investment Advisors LLC grew its holdings in Sarepta Therapeutics by 23.1% during the fourth quarter. Nisa Investment Advisors LLC now owns 1,317 shares of the biotechnology company’s stock valued at $160,000 after purchasing an additional 247 shares during the period. Finally, Fifth Third Bancorp grew its holdings in Sarepta Therapeutics by 219.7% during the fourth quarter. Fifth Third Bancorp now owns 1,832 shares of the biotechnology company’s stock valued at $223,000 after purchasing an additional 1,259 shares during the period. Institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.